Brokerages Set Biogen Inc. (NASDAQ:BIIB) PT at $227.07

Shares of Biogen Inc. (NASDAQ:BIIB) have been given a consensus recommendation of “Moderate Buy” by the thirty-three ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $227.0714.

Several analysts recently issued reports on the stock. Evercore began coverage on shares of Biogen in a report on Friday, May 15th. They set an “outperform” rating for the company. Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research report on Monday, July 13th. Barclays upped their price target on shares of Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. Guggenheim raised their price target on Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, TD Cowen lifted their price objective on Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Biogen during the second quarter worth approximately $3,453,878,000. Orbimed Advisors LLC acquired a new position in shares of Biogen in the 1st quarter worth approximately $11,293,000. LSV Asset Management boosted its holdings in shares of Biogen by 3.3% in the 4th quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock worth $55,756,000 after acquiring an additional 9,976 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in Biogen during the 4th quarter worth approximately $2,006,000. Finally, Systematic Financial Management LP grew its position in Biogen by 256.3% during the 4th quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock worth $2,928,000 after acquiring an additional 11,970 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen Price Performance

Shares of BIIB stock opened at $216.78 on Friday. The stock’s 50 day simple moving average is $205.53 and its 200 day simple moving average is $194.58. Biogen has a twelve month low of $131.52 and a twelve month high of $222.15. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The company has a market capitalization of $32.03 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 6.75 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. During the same quarter in the prior year, the business earned $5.47 earnings per share. The company’s revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, research analysts predict that Biogen will post 12.39 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.